CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Phase 2

Terminated

Conditions: Melanoma
Advanced Melanoma
Metastatic Melanoma
Unresectable Melanoma

Interventions: Drug: CMP-001
Drug: Nivolumab

Registration Number: NCT04698187

Lead Sponsor: Regeneron Pharmaceuticals

Brief Summary: CMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma.

The primary objective of the study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

The secondary objectives are to:

* To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

* To evaluate the efficacy of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

* To assess the pharmacokinetic (PK) profile of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

* To assess and describe the immunogenicity of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

Detailed Description: Former Sponsor Checkmate Pharmaceuticals

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 44

Inclusion Criteria

Subjects enrolled in the study must meet all of the following inclusion criteria to be eligible.

Histopathologically-confirmed diagnosis of malignant melanoma that is metastatic or unresectable at Screening.
Known BRAF mutation status; if BRAF V600 mutation positive, must have had prior treatment with a local Health Authority approved BRAF inhibitor, with or without mitogen-activated protein kinase inhibitor. Patients with BRAF V600 mutations who refuse a BRAF inhibitor will not be eligible.
Refractory to PD-1 blockade either as monotherapy or in combination with other therapies, as defined by the following criteria:
1. Received treatment with a Food and Drug Administration approved PD-1 blocking antibody for 12 weeks or longer.
2. Have PD (according to RECIST v1.1) within 12 weeks of the last dose of a PD-1 blocking antibody, either as monotherapy or in combination with other agents.
Evidence of confirmed PD must be established by investigator assessment at least 4 weeks after the initial date of PD. The second assessment may serve as the Baseline for this study if completed within 30 days before to the start of study treatment. NOTE: in subjects with histologically confirmed recurrence on or after adjuvant PD-1 blocking antibody, confirmatory imaging is not required.
Measurable disease, as defined by RECIST v1.1 and all of the following:
1. At least 1 accessible lesion amenable to repeated IT injection.
2. One or more measurable lesions at least 1 cm in diameter that are not intended for CMP 001 injection and can be followed as target lesions per RECIST v1.1.
3. Documented disease progression in any lesion that was previously radiated in order to serve as a target lesion.
Able to provide tissue from a core or excisional biopsy (fine needle aspirate is not sufficient). A fresh tissue biopsy (within 90 days before the start of study treatment) is preferred but an archival sample is acceptable if no intervening therapy was received. Note: For tissue sampling details, please refer to the laboratory manual.
Adequate organ function based on most recent laboratory values within 3 weeks before first dose of study treatment on Week 1 Day 1 (W1D1):
1. Bone marrow function:
  - neutrophil count ≥ 1500/mm3
  - platelet count ≥ 100,000/mm3
  - hemoglobin concentration ≥ 9 g/dL
  - white blood cells ≥ 2000/mm3
2. Liver function:
  - total bilirubin ≤ 1.5 times the upper limit of normal (ULN) with the following exception: patients with Gilbert Disease total serum bilirubin ≤ 3 times ULN
  - aspartate aminotransferase and alanine aminotransferase ≤ 3 times the ULN
3. Lactate dehydrogenase ≤ 2 times the ULN
4. Renal function: estimated (Cockcroft-Gault) or measured creatinine clearance ≥ 30 mL/min.
5. Coagulation:
  - International normalized ratio or prothrombin time (PT) ≤ 1.5 times ULN, unless subject is receiving anticoagulant therapy, as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
  - Activated partial thromboplastin time or PTT ≤ 1.5 times ULN, unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Age ≥ 18 years at time of consent.
Eastern Cooperative Oncology Group Performance Status of 0 to 1 at Screening.
Capable of understanding and complying with protocol requirements.
Women of childbearing potential must have negative serum pregnancy test before dosing at W1D1 and be willing to use an adequate method of contraception from the time of consent until at least 150 days after last dose of study treatment.
Able and willing to provide written informed consent and to follow study instructions. Subjects unable to provide written informed consent on their own behalf will not be eligible for the study.

Exclusion Criteria

Subjects presenting with any of the following will not qualify for entry into the study:

Uveal, acral, or mucosal melanoma.
Received radiation therapy (or other nonsystemic therapy) within 2 weeks before first dose of study treatment on W1D1. Patients should have recovered (ie, Grade ≤1 or at baseline) from radiation-related toxicities.
Treatment with complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before start of study treatment. Refer to Section 4.4. for prohibited therapies.
Received systemic pharmacologic doses of corticosteroids ≥10 mg/day prednisone within 30 days before first dose of study treatment on W1D1.
1. Subjects who are currently receiving steroids at a prednisone-equivalent dose of ≤ 10 mg/day do not need to discontinue steroids before enrollment.
2. Replacement doses, topical, ophthalmologic, and inhalational steroids are permitted.
3. Stress-dose corticosteroids will be required in subjects with adrenal insufficiency
History of immune-related AE that required permanent discontinuation of PD-1 blocking antibody.
Not fully recovered from AEs (to Grade 1 or less [per CTCAE v5.0], with the exception of persistent adverse events or sequelae, eg, vitiligo, alopecia, hypothyroidism, diabetes mellitus, and adrenal and/or pituitary insufficiency) due to prior treatment.

NOTE: Subjects previously treated with a CTLA-4-blocking antibody, subjects receiving corticosteroids with daily doses > 5 mg and ≤ 10 mg of prednisone equivalent for 2 weeks, and subjects with clinical symptoms and/or laboratory findings suggesting risk for adrenal insufficiency should undergo diagnostic tests for adrenal insufficiency via local laboratory.
Active pneumonitis or history of noninfectious pneumonitis that required steroids.
Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to poorly controlled hypertension, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association Class II or greater), pericarditis within the previous 6 months, cerebrovascular accident, or implanted or continuous use of a pacemaker or defibrillator.
Known history of immunodeficiency.
Known additional malignancy that is progressing or required active treatment within the past 3 years. Exceptions include cancers that have undergone potentially curative therapy, eg, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, localized prostate cancer with prostate-specific antigen level below 4.0 ng/mL, in situ cervical cancer on biopsy or a squamous intraepithelial lesion on Papanicolaou smear, and thyroid cancer (except anaplastic), in situ breast cancer, and adjuvant hormonal therapy for breast cancer > 3 years from curative-intent surgical resection.
Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment.
Untreated, symptomatic, or enlarging central nervous system metastases or carcinomatous meningitis (including leptomeningeal metastases from solid tumors).
Prior allogenic tissue/solid organ transplant.
Active infection requiring systemic therapy.
Known or suspected active infection with severe acute respiratory syndrome coronavirus 2 virus.
Known or suspected active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus (testing is not required unless suspected).
Received a live virus/attenuated vaccination within 30 days before first dose of study treatment on W1D1.
Received blood products (including platelets or red blood cells) or colony stimulating factors (including granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, or recombinant erythropoietin) within 30 days before the start of Screening.
History of allergy or hypersensitivity to nivolumab and/or any of its excipients.
Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator would make the subject unable to cooperate or participate in the study.
Participation in another clinical study of an investigational anticancer therapy or device within 30 days before first dose of study treatment on W1D1. Participation in the follow-up phase (receiving no study treatment) of a prior study is allowed.
Requires prohibited treatment (ie, non-protocol specified anticancer pharmacotherapy, surgery, or radiotherapy) for treatment of malignant tumor.
Has a life expectancy of less than 3 months and/or has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain) in the opinion of the treating Investigator.
Received previous CMP-001 treatment.
Pregnant or breastfeeding or expecting to conceive or donate eggs within the projected duration of the study, from the time of consent until at least 150 days after last dose of study treatment for women.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CMP-001 and Nivolumab	Nivolumab	All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
CMP-001 and Nivolumab	CMP-001	All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.

Primary Outcome Measures

Name	Time	Method
Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)	Up to approximately 24 months (107 weeks)	ORR, defined as the percentage of participants who have confirmed best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Any Serious TEAE, and Any TEAE Leading to Discontinuation or Death	Up to approximately 24 months (107 weeks)	Number of participants with any treatment-emergent adverse event (TEAE), any serious TEAE, and any TEAE leading to discontinuation or death reported.
Severity of TEAEs as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)	Up to approximately 24 months (107 weeks)	Number of participants per NCI CTCAE version 5.0 Adverse Event Grade reported: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limited self-care activities of daily living Grade 4 Life-threatening consequences: urgent intervention indicated Grade 5 Death related to adverse event
Time to Response (TTR) by BICR	Up to approximately 28 months (122 weeks)	TTR, defined as the time from the first dose date of the study treatment to the first time when criteria are first met for CR or PR, whichever occurred first, per RECIST v1.1 by BICR.
Time to Response (TTR) by Investigator	Up to approximately 28 months (122 weeks)	TTR, defined as the time from the first dose date of the study treatment to the first time when criteria are first met for CR or PR, whichever occurred first, per RECIST v1.1 by Investigator.
Duration of Response (DOR) by BICR	Up to approximately 28 months (122 weeks)	DOR, defined as time from the date of first documented response (CR or PR) to the date of documented progressive disease (PD), based on RECIST v1.1 by BICR.
Duration of Response (DOR) by Investigator	Up to approximately 28 months (122 weeks)	DOR, defined as time from the date of first documented response (CR or PR) to the date of documented progressive disease (PD), based on RECIST v1.1 by Investigator.
Confirmed ORR in Non-injected Target Lesions by Investigator	Up to approximately 24 months (107 weeks)	Confirmed ORR, defined as the percentage of participants in the analysis set who had confirmed BOR of CR or PR based on RECIST v1.1 as assessed by Investigator.
Progression-free Survival (PFS) by BICR	Up to approximately 31 months (135 weeks)	PFS, defined as time from date of first dose of study treatment to date of documented PD based on RECIST v1.1 by BICR or death, whichever occurred first.
Progression-free Survival (PFS) by Investigator	Up to approximately 31 months (135 weeks)	PFS, defined as time from date of first dose of study treatment to date of documented PD based on RECIST v1.1 by Investigator or death, whichever occurred first.
Overall Survival (OS) by Investigator	Up to approximately 32 months (139 weeks)	OS, defined as the time from the first dose date of the study treatment to the date of death from any cause.
Immune Objective Response Rate (iORR) by Investigator	Up to approximately 24 months (107 weeks)	iORR, defined as the percentage of participants with an immune best overall response (iBOR) of confirmed immune complete response (iCR) or confirmed immune partial response (iPR) based on immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by Investigator assessment.
Immune Duration of Response (iDOR) by Investigator	Up to approximately 28 months (122 weeks)	iDOR, defined as the time from the date of the first immune response (iCR or iPR) to the date of immune confirmed progressive disease (iCPD) by Investigator assessment.
Immune Progression-free Survival (iPFS) by Investigator	Up to 9 months (approximately 39 weeks)	iPFS, defined as the time from the first dose date of the study treatment to date of immune confirmed progressive disease (iCPD) per iRECIST by Investigator assessment or death, whichever occurred first.
Maximum Observed Serum Concentration	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)	Assess the pharmacokinetic (PK) profile for maximum observed serum concentration.
Area Under the Serum Concentration-Time Curve From Time Zero to the Last Quantifiable Time Point	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)	Assess the PK profile for area under the serum concentration-time curve from time zero to the last quantifiable time point.
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)	Assess the PK profile for area under the serum concentration-time curve from time zero extrapolated to infinity.
Terminal Elimination Half-Life	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)	Assess the PK profile for terminal elimination half-life.
Number of Participants With Immunogenicity as Measured by Anti-Qbeta Antibodies (ADA)	Up to approximately 24 months (107 weeks)	Development of anti-Qbeta antibodies in participants with refractory unresectable or metastatic melanoma.

Trial Locations

Locations (25): City of Hope National Medical Center, Robert Kang, MD
🇺🇸
Duarte, California, United States
University Cancer & Blood Center
🇺🇸
Athens, Georgia, United States
University of Iowa
🇺🇸
Iowa City, Iowa, United States
GenesisCare USA
🇺🇸
Jacksonville, Florida, United States
California Cancer Associates for Research & Excellence, Inc.
🇺🇸
San Marcos, California, United States
UCLA Hematology-Oncology
🇺🇸
Los Angeles, California, United States
Hartford Healthcare
🇺🇸
Hartford, Connecticut, United States
Emory University Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
The Ohio State University
🇺🇸
Columbus, Ohio, United States
Sammons Cancer Center
🇺🇸
Dallas, Texas, United States
Seattle Cancer Care Alliance
🇺🇸
Seattle, Washington, United States
University of Utah- Huntsman Cancer Institute
🇺🇸
Salt Lake City, Utah, United States
Mayo Clinic
🇺🇸
Phoenix, Arizona, United States
University of Colorado- Denver
🇺🇸
Denver, Colorado, United States
Duke University Cancer Institute
🇺🇸
Durham, North Carolina, United States
Stephenson Cancer Center
🇺🇸
Oklahoma City, Oklahoma, United States
Orlando Health
🇺🇸
Orlando, Florida, United States
Cleveland Clinic Florida
🇺🇸
Weston, Florida, United States
University of Louisville Health Care
🇺🇸
Louisville, Kentucky, United States
Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States
Columbia University Herbert Irving Comprehensive Cancer Center
🇺🇸
New York, New York, United States
University of Pittsburgh Medical Center
🇺🇸
Pittsburgh, Pennsylvania, United States
Thomas Jefferson University
🇺🇸
Philadelphia, Pennsylvania, United States